Patients are generally treated with the triplet regimen as continuous therapy. If a patient is eligible for ASCT and it was deferred at relapse, three to six induction cycles are usually done before stem cell harvest.
ASCT improves median overall survival in multiple myeloma by approximately 12 months, but randomized trials demonstrated a similar overall survival between both early ASCT (immediately after four cycles of induction therapy) and delayed ASCT (at the time of relapse as salvage therapy).
Learn more about treatment of multiple myeloma.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maria-Victoria Mateos. Fast Five Quiz: Relapsed/Refractory Multiple Myeloma - Medscape - Jan 11, 2022.